Cargando…
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
BACKGROUND: Rearranged during transfection (RET) has been proven to be a tumorigenic target in non-small cell lung cancers (NSCLCs). In RET-rearranged NSCLCs, molecular features and their impact on prognosis were not well illustrated, and the activity of mainstay therapeutics has not currently been...
Autores principales: | Lu, Chang, Dong, Xiao-Rong, Zhao, Jun, Zhang, Xu-Chao, Chen, Hua-Jun, Zhou, Qing, Tu, Hai-Yan, Ai, Xing-Hao, Chen, Xiao-Feng, An, Gai-Li, Bai, Jun, Shan, Jin-Lu, Wang, Yi-Na, Yang, Shuan-Ying, Liu, Xiang, Zhuang, Wu, Wu, Hui-Ta, Zhu, Bo, Xia, Xue-Feng, Chen, Rong-Rong, Gu, De-Jian, Xu, Hua-Min, Wu, Yi-Long, Yang, Jin-Ji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160902/ https://www.ncbi.nlm.nih.gov/pubmed/32295619 http://dx.doi.org/10.1186/s13045-020-00866-6 |
Ejemplares similares
-
Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018) -
Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022) -
Palladium-catalyzed enantioselective rearrangement of dienyl cyclopropanes
por: Xu, Qi, et al.
Publicado: (2023) -
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019) -
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)